Human Papillomavirus Protein E6 (E6)-Pipeline Review, H2 2017 : Pharmaceuticals Industry Research Report – MRH

Market Research HUB Market Research HUB

Albany, US, 2017-Nov-03 — /EPR Network/:  Market Research Hub (MRH) has recently added a new report to its vast online database. This research study is titled as “Human Papillomavirus Protein E6 (E6)-Pipeline” 2017 which presents an in-depth study about the production, consumption, market volume, revenue (million USD) and market share across different geographical regions.

Request For Free Sample – https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361378

Human Papillomavirus Protein E6 (E6)-The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

The report Human Papillomavirus Protein E6 (E6)-Pipeline Review, H2 2017 outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Womens Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer and Oropharyngeal Cancer.

Browse Full Report With TOC – https://www.marketresearchhub.com/report/human-papillomavirus-protein-e6-e6-pipeline-review-h2-2017-report.html

Scope

– The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
– The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
– The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5

Global Markets Direct Report Coverage 5
Human Papillomavirus Protein E6 (E6)-Overview 6
Human Papillomavirus Protein E6 (E6)-Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 14
Human Papillomavirus Protein E6 (E6)-Therapeutics Assessment 16
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Human Papillomavirus Protein E6 (E6)-Companies Involved in Therapeutics Development 21

Abion Inc 21
BioNTech AG 21
Cancer Research Technology Ltd 21
Etubics Corp 22
Genexine Inc 22
Hookipa Biotech AG 23
Inovio Pharmaceuticals Inc 23
MedImmune LLC 24
Rottapharm Biotech Srl 24
Selecta Biosciences Inc 24
Transgene SA 25

Human Papillomavirus Protein E6 (E6)-Drug Profiles 26
ABN-301-Drug Profile 26
Antibodies to Inhibit E6 for HPV Associated Cancer-Drug Profile 27
BVAC-C-Drug Profile 28
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia-Drug Profile 29
ETBX-041-Drug Profile 30
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia-Drug Profile 31
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer-Drug Profile 32
GX-188E-Drug Profile 33

Continue…..

Enquire About this Report –  https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1361378

About Market Research Hub:            

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

 

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: press@marketresearchhub.com

Website: https://www.marketresearchhub.com/

Read More Related News: https://www.industrynewsanalysis.com/

 

 

 

Matched content

Editor’s pick

Express Press Release Distribution